Carboplatin + Paclitaxel
Treatment for Ovarian Cancer
Typical Dosage: Carboplatin AUC 5-6 + Paclitaxel 175 mg/m2 IV q3w for 6 cycles
Effectiveness
75%
Safety Score
30%
Clinical Trials
347
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
Carboplatin AUC 5-6 + Paclitaxel 175 mg/m2 IV q3w for 6 cycles
Time to Effect
1-2 months
Treatment Duration
4.5-6 months
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$7,500
Side Effect Mgmt:$7,500
Total Annual:$20,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
2
Outcome-Based Costs
Cost per Responder
$26,667
Cost per Remission
$50,000
Carboplatin + Paclitaxel Outcomes
for Ovarian Cancer
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+75%
Remission Rate
+40%
Common Side Effects
Myelosuppression (Neutropenia, Anemia)
+70%
Alopecia
+85%
Peripheral Neuropathy
+40%
Nausea/Vomiting
+60%
Fatigue
+75%
Sources:
Active Clinical Trials
4 active trials recruiting for Carboplatin + Paclitaxel in Ovarian Cancer
Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer
NCT07663513NOT YET RECRUITINGPHASE2
36 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 1, 2026
The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression
NCT07401654NOT YET RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Started: Jan 31, 2026
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
NCT07407452NOT YET RECRUITINGPHASE2
50 participants
INTERVENTIONAL
Nanjing, China
Started: Feb 1, 2026
Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer
NCT03025477RECRUITINGPHASE2
84 participants
INTERVENTIONAL
Dijon, France +6 more
Started: Oct 1, 2016
Completed Clinical Trials
8 completed trials for Carboplatin + Paclitaxel in Ovarian Cancer
Salvage Ovarian FANG™ Vaccine + Carboplatinum
NCT01867086COMPLETEDPHASE2
1 participants
INTERVENTIONAL
Dallas, United States
Started: Jun 1, 2013
Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV
NCT00231075COMPLETEDPHASE2
75 participants
INTERVENTIONAL
Eaubonne, France +1 more
Started: Jan 1, 2001
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
NCT02107937COMPLETEDPHASE2
136 participants
INTERVENTIONAL
Brno, Czechia +12 more
Started: Nov 1, 2013
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
NCT00193297COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Started: Feb 1, 2002
Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer
NCT05963334COMPLETEDPHASE1, PHASE2
49 participants
INTERVENTIONAL
Cairo, Egypt
Started: Jan 1, 2015
Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer
NCT02312661COMPLETEDPHASE1
15 participants
INTERVENTIONAL
Groningen, Netherlands
Started: Oct 5, 2015
Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin
NCT00181701COMPLETEDPHASE2
46 participants
INTERVENTIONAL
Started: Oct 1, 2004
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
NCT01616303COMPLETEDPHASE2
97 participants
INTERVENTIONAL
Farmington, United States +1 more
Started: Jun 15, 2012
Showing 20 of 368 total trials